Erin Quirk's most recent trade in Terns Pharmaceuticals Inc was a trade of 150,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 23, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc | Erin Quirk | President, Head of R&D | 23 Jan 2024 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
Terns Pharmaceuticals Inc | Quirk Erin | President, Head of R&D | 23 Jan 2024 | 75,000 | 75,000 | - | 0 | Common Stock | ||
Terns Pharmaceuticals Inc | Erin Quirk | President, Head of R&D | 01 Feb 2023 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | ||
Terns Pharmaceuticals Inc | Erin Quirk | President and CMO | 28 Sep 2021 | 142,500 | 142,500 | - | - | Stock Option (Right to Buy) |